Biome Australia Ltd (AU:BIO)
Australian Market

Biome Australia Ltd (BIO) Share Price & Analysis


BIO Stock Chart & Stats

Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.07 - AU$0.44
Previous CloseAU$0.37
Average Volume (3M)329.65K
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)AU$5.49M
Total Debt (Recent Filing)AU$467.05K
Price to Earnings (P/E)
Jul 23, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume329,655
Standard DeviationN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Options Prices

Currently, No data available

Ownership Overview

12.06% Insiders
0.00% Other Institutional Investors
87.94% Public Companies and
Individual Investors


What was Biome Australia Ltd’s price range in the past 12 months?
Biome Australia Ltd lowest share price was AU$0.07 and its highest was AU$0.43 in the past 12 months.
    What is Biome Australia Ltd’s market cap?
    Currently, no data Available
    When is Biome Australia Ltd’s upcoming earnings report date?
    Biome Australia Ltd’s upcoming earnings report date is Jul 23, 2024 which is in 35 days.
      How were Biome Australia Ltd’s earnings last quarter?
      Biome Australia Ltd released its earnings results on Feb 21, 2024. The company reported -AU$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.008.
        Is Biome Australia Ltd overvalued?
        According to Wall Street analysts Biome Australia Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Biome Australia Ltd pay dividends?
          Biome Australia Ltd does not currently pay dividends.
          What is Biome Australia Ltd’s EPS estimate?
          Biome Australia Ltd’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Biome Australia Ltd have?
          Biome Australia Ltd has 212,959,500 shares outstanding.
            What happened to Biome Australia Ltd’s price movement after its last earnings report?
            Biome Australia Ltd reported an EPS of -AU$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Biome Australia Ltd?
              Currently, no hedge funds are holding shares in AU:BIO

              Biome Australia Ltd Stock Smart Score

              Company Description

              Biome Australia Ltd

              Biome Australia Ltd licences, develops, and markets evidence-based, complementary medicines, including nutraceuticals food-based vitamins and weight management products and live biotherapeutics. The firm owns brands namely; Activated Nutrients: a range of completely organic, plant-based, all-in-one nutritional products; Activated Probiotics: a first-of-its-kind range of clinically-backed precision probiotics; and AXP TM, a certified range of performance products for athletes. Domestically it caters to Australia and In international markets, the Group distributes and markets its Activated Probiotics range in the United Kingdom and New Zealand through independent health practitioners. Key revenue is derived from domestic sales.
              Similar Stocks
              Price & Change
              Bio-Gene Technology Ltd.
              Holista Colltech Limited
              Popular Stocks
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis